Translation and commercialization of regenerative medicines

Organized by Julia Polak, Christopher A. Bravery and Catherine Prescott

Introduction
Translation and commercialization of regenerative medicines 5675
J. Polak, C. A. Bravery & C. Prescott

Articles
Safety paradigm: genetic evaluation of therapeutic grade human embryonic stem cells 5677

Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues 5689
H. Abdulrazzak, D. Moschidou, G. Jones & P. V. Guillot

Alignment hierarchies: engineering architecture from the nanometre to the micrometre scale 5707

Engineering extracellular matrix through nanotechnology 5717
C. M. Kelleher & J. P. Vacanti

Human endothelial stem/progenitor cells, angiogenic factors and vascular repair 5731
S. M. Watt, A. Athanassopoulos, A. L. Harris & G. Tsaknakis

Tumorigenicity of pluripotent stem cells: biological insights from molecular imaging 5753
N. G. Kooreman & J. C. Wu

Stroke in atrial fibrillation—hope on the horizon? 5765
S. Jamil-Copley & P. Kanagaratnam

Regenerative medicine: the emergence of an industry 5771
R. M. Nierm

Regenerative medicine. Opportunities and challenges: a brief overview 5777
D. J. Polak

Regenerative nanomedicines: an emerging investment prospective? 5783
C. Prescott

Regulating interface science healthcare products: myths and uncertainties 5789
C. A. Bravery